Analysts Anticipate Radius Health Inc (RDUS) Will Post Earnings of -$1.01 Per Share
Brokerages expect that Radius Health Inc (NASDAQ:RDUS) will report earnings of ($1.01) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Radius Health’s earnings. Radius Health posted earnings of ($1.31) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 22.9%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 1st.
On average, analysts expect that Radius Health will report full year earnings of ($4.14) per share for the current year. For the next year, analysts anticipate that the company will post earnings of ($4.04) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Radius Health.
Radius Health (NASDAQ:RDUS) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.99) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.35) by $0.36. The firm had revenue of $22.63 million for the quarter, compared to analysts’ expectations of $20.84 million. Radius Health had a negative return on equity of 110.71% and a negative net margin of 444.70%.
NASDAQ RDUS traded up $0.81 during trading on Friday, hitting $20.55. The stock had a trading volume of 66,403 shares, compared to its average volume of 1,260,489. The stock has a market capitalization of $936.82 million, a price-to-earnings ratio of -3.55 and a beta of 1.04. The company has a debt-to-equity ratio of 1.26, a quick ratio of 5.26 and a current ratio of 5.39. Radius Health has a 12 month low of $18.88 and a 12 month high of $41.16.
In related news, major shareholder Growth N. V. Biotech acquired 169,363 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were bought at an average price of $20.83 per share, for a total transaction of $3,527,831.29. Following the purchase, the insider now directly owns 6,460,913 shares in the company, valued at approximately $134,580,817.79. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of the company’s stock in a transaction dated Wednesday, July 25th. The shares were bought at an average price of $27.28 per share, for a total transaction of $1,364,000.00. Following the purchase, the insider now owns 6,250,913 shares in the company, valued at $170,524,906.64. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 439,363 shares of company stock worth $10,043,131. Company insiders own 3.42% of the company’s stock.
Several institutional investors have recently made changes to their positions in RDUS. Alps Advisors Inc. raised its stake in shares of Radius Health by 21.0% during the 1st quarter. Alps Advisors Inc. now owns 59,808 shares of the biopharmaceutical company’s stock worth $2,150,000 after purchasing an additional 10,396 shares in the last quarter. Swiss National Bank increased its holdings in shares of Radius Health by 5.6% during the 1st quarter. Swiss National Bank now owns 57,000 shares of the biopharmaceutical company’s stock worth $2,049,000 after acquiring an additional 3,000 shares during the last quarter. State of Wisconsin Investment Board increased its holdings in shares of Radius Health by 48.1% during the 1st quarter. State of Wisconsin Investment Board now owns 38,500 shares of the biopharmaceutical company’s stock worth $1,384,000 after acquiring an additional 12,500 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Radius Health by 4.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 191,510 shares of the biopharmaceutical company’s stock worth $6,883,000 after acquiring an additional 8,935 shares during the last quarter. Finally, Aperio Group LLC acquired a new position in shares of Radius Health during the 1st quarter worth approximately $231,000.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Featured Story: How do investors use RSI to grade stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.